DARPin-conjugated radioligand therapeutic / Novartis, Molecular Partners - LARVOL DELTA

DARPins as powerful targeting agents for radioligand therapeutics (AACR 2023) - "Together with the fact that high-affinity DARPins can be generated against a large variety of tumor targets, we conclude that our platform provides a powerful basis for the development of next-generation RLTs. Several DARPin-RLT programs in indications with high unmet medical need are currently in development."

Oncology

Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology (GlobeNewswire) - "Molecular Partners AG...announced a collaboration with Novartis in the form of a license agreement to develop, manufacture and commercialize DARPin-conjugated radioligand therapies (DARPin-RLTs). The collaboration will combine Molecular Partners’ industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis....Under the agreement, both parties will collaborate on the discovery and optimization of the therapeutic candidates. Novartis would be responsible for all clinical development and commercialization activities."

Licensing / partnership • Oncology